This approach is supported by the results of the BEYOND trial [8], showing that it is possible and safe to switch from a basal-bolus regimen to a once-daily fixed-combination injection added to BI, with similar glucose control, fewer insulin doses, fewer injections daily, and less hypoglycemia. Here, INS is linked to Hypoglycemia.